IOP-lowering effect and tolerability of prostaglandin analogues in primary open-angle glaucoma and ocular hypertension as risk factors for glaucoma progression

Abstract

A.V. Belogurova1, E.N. Eskina1, J.G. Oganezova2 1LLC “Сlinic “Sphere”, Moscow, Russian Federation 2Pirogov Russian National Research Medical University, Moscow, Russian Federation Glaucoma is still one of the leading causes of irreversible low vision and blindness worldwide. Effective treatment for primary open-angle glaucoma (POAG) is an important issue in modern ophthalmology. Topical IOP-lowering agents are prescribed to control glaucoma and to normalize IOP. 60% to 80% of glaucoma patients receive exactly medical treatment, i.e., daily instillations of eye drops. Preservative-containing antiglaucoma drops induce secondary “dry eye” syndrome, conjunctival hyperemia, thereby reducing the patient’s adherence to treatment and, in some cases, provoking self-abolition of antiglaucoma drugs by patients. The article reviews the data on IOP-lowering effect and tolerability of preservative-free tafluprost 0.0015% in patients with POAG and ocular hypertension who have switched from preservative-containing prostaglandin analogues. Preservative-free tafluprost characterized by high IOP-lowering efficacy keeps the IOP under control when switching to this agent. Tafluprost has also good tolerability in terms of improved subjective complaints and signs of dry eye as well as objective ocular surface criteria. Switching from preservative-containing tafluprost to preservative-free formulation is reasonable and can improve compliance due to its efficacy. Keywords: glaucoma, intolerance, treatment, dry eye, preservatives, preservative-free, compliance, efficacy, tafluprost, Taflotan. For citation: Belogurova A.V., Eskina E.N., Oganezova J.G. IOP-lowering effect and tolerability of prostaglandin analogues in primary open-angle glaucoma and ocular hypertension as risk factors for glaucoma progression. Russian Journal of Clinical Ophthalmology. 2019;19(1):21–26. About the authors: 1Alyona V. Belogurova — MD, PhD, ophthalmologist; 1Erika N. Eskina — MD, PhD, Professor, medical director; 2Janna G. Oganezova — MD, PhD, Assistant Professor of the Ophthalmological Department. 1LLC “Clinic “Sphere”. 10, Starokachalovskaya str., Moscow, 117628, Russian Federation. 2Pirogov Russian National Research Medical University. 1, Ostrovityanova str., Moscow, 117997, Russian Federation. Contact information: Alyona V. Belogurova, e-mail: [email protected]. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 19.12.2018.